menu toggle
Friday, November 28
Our offices will also be closed on Friday, November 28. While some deliveries will take place on Friday according to network operations, our Customer Service and Customer Systems Support teams will be unavailable. Please review our full holiday schedule for more detailed information and to plan your orders accordingly.
Action required: New logo and email address for invoices starting October 18
Ensure that you’re prepared to continue receiving invoices electronically.

October 23, 2025

Now available BEIZRAY®

BEIZRAY® (docetaxel) injection, for intravenous use, is a microtubule inhibitor indicated for:

  • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC
  • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC
  • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer
  • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN

Please see full prescribing information here.